ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine

Why It Matters

Whooping cough cases are rising globally, and existing vaccines offer limited protection, so ILiAD’s advancement could reshape the market and improve public health outcomes. The sizable funding also reflects growing investor appetite for innovative vaccine platforms.

Key Takeaways

• $115M Series B funding secured
• Funds target Phase 3 trials for pertussis vaccine
• Oversubscribed round signals strong investor confidence
• Vaccine aims to improve durability over existing shots
• ILiAD positions for market entry by 2028

Pulse Analysis

The resurgence of whooping cough across high‑income and emerging markets has exposed the shortcomings of the acellular pertussis vaccines that dominate today’s immunization schedules. While safer than the older whole‑cell formulations, these vaccines generate waning immunity, leading to periodic outbreaks and heightened concern among public‑health officials. Analysts estimate that global pertussis vaccine sales could exceed $2 billion by 2030, driven by booster demand and newer product pipelines. In this climate, a vaccine that delivers longer‑lasting protection is not just desirable—it is becoming a public‑health imperative.

ILiAD Biotechnologies leverages a proprietary antigen‑display platform designed to elicit robust, durable immune responses against Bordetella pertussis. The newly closed $115 million Series B round, which was oversubscribed, brings together venture capital firms, strategic biotech investors, and government‑linked health funds. The infusion will primarily finance a pivotal Phase 3 trial slated to enroll thousands of participants across North America and Europe, with primary endpoints focused on efficacy durability and safety. By securing this capital, ILiAD accelerates its timeline toward regulatory submission, potentially filing a New Drug Application by 2027.

The financing milestone signals a broader shift in vaccine financing, where investors are willing to back late‑stage development of differentiated immunizations despite the traditionally high risk. If ILiAD’s candidate meets its Phase 3 goals, it could capture a sizable share of the pertussis market, challenge incumbents such as Sanofi and GlaxoSmithKline, and open pathways for combination vaccines. Moreover, the success of this round may encourage further capital flow into next‑generation vaccine platforms, reinforcing the industry’s move toward more effective, long‑acting prophylactics.

Deal Summary

ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.